Schering-Plough Takes The Long Road To Early Stage Hep C R&D
This article was originally published in The Pink Sheet Daily
Executive Summary
The firm is conducting a 24-week, Phase II study in non-responders to pegylated interferon and ribavirin.
You may also be interested in...
Schering-Plough CEO Fred Hassan: An Interview With “The Pink Sheet” DAILY (Part 3 of 3)
Hassan discusses Schering’s late-stage pipeline, including the protease inhibitor boceprevir for hepatitis C and SCH 530348, a thrombin receptor agonist intended as an add-on to Plavix therapy.
Schering-Plough CEO Fred Hassan: An Interview With “The Pink Sheet” DAILY (Part 3 of 3)
Hassan discusses Schering’s late-stage pipeline, including the protease inhibitor boceprevir for hepatitis C and SCH 530348, a thrombin receptor agonist intended as an add-on to Plavix therapy.
Interim Phase II Telaprevir Data Point To Possible Shortened Hep C Treatment Course
Vertex hopes to base Phase III trial design on 12-week dosing with telaprevir plus standard of care followed by standard of care for 12 weeks.